Peer-reviewed veterinary case report
Vaccine protecting cats from both types of feline calicivirus
By Yang, Yupeng et al.·Published in Frontiers in immunology·2024·Harbin Veterinary Research Institute, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: An effectively protective VLP vaccine candidate for both genotypes of feline calicivirus.
- Species:
- cat
Plain-English summary
A group of cats was vaccinated with a new type of vaccine designed to protect against feline calicivirus (FCV), a common virus that can make cats sick. The vaccine, called DL39-VLPs, was given as an injection and showed strong results in preventing the virus from causing illness. Cats that received the vaccine did not show significant symptoms and had much lower levels of the virus in their bodies compared to those that were not vaccinated. This new vaccine could be a safe and effective way to help protect cats from FCV infection.
People also search for: cat calicivirus vaccine · feline calicivirus symptoms · how to prevent cat virus
Abstract
Feline calicivirus (FCV) is one of the most widespread pathogens affecting feline animals. Currently, FCV is believed to be divisible into two genotypes, with prevalent strains encompassing both GI and GII. Vaccination is the primary means of preventing FCV infection, yet traditional inactivated or attenuated vaccines theoretically pose potential safety concerns. In this study, a virus-like particles (VLPs), named DL39-VLPs, was constructed, using thegene of FCV DL39 strain with broad neutralizing and protective properties as a template through insect cell expression system. Cats were immunized with a 50 μg dose of DL39-VLPs mixed with an oily adjuvant via subcutaneous injection in the neck. For feline antisera positive for DL39-VLPs, the titer range in neutralization tests against prevalent GI strains ranged from 1:151 to 1:538, whereas the titer range in neutralization tests against prevalent GII strains was between 1:65 and 1:113. Challenge trials demonstrated that cats immunized with DL39-VLPs exhibited no significant clinical symptoms and had significantly reduced viral shedding and viremia compared to the challenged control group. Ultimately, a safe and highly protective VLP vaccine candidate, DL39-VLPs, was developed, which provides an important tool for the prevention and control of FCV infection.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39759504/